Frédéric Blanchard

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.

M. Padrines, S. Théoleyre, D. Heymann, 2004, Biochimica et biophysica acta.

Close phenotypic and functional similarities between human and murine alphabeta T cells expressing invariant TCR alpha-chains.

M. Bonneville, H. Vié, A. Necker, 1997, Journal of immunology.

Production and characterization of monoclonal antibodies against the leukemia inhibitory factor low affinity receptor, gp190.

A. Vernallis, J. Taupin, F. Blanchard, 1997, Journal of immunological methods.

Modulation of LIF expression in human melanoma cells by oncostatin M.

D. de Groote, D. Heymann, F. Blanchard, 1995, Immunology letters.

Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B

B. Le Goff, D. Heymann, A. Moreau, 2007, The Journal of pathology.

Loss of oncostatin M receptor β in metastatic melanoma cells

B. Dréno, A. Khammari, F. Blanchard, 2007, Oncogene.

Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease

B. Le Goff, C. Gabay, A. Bourreille, 2015, Clinical and experimental immunology.

Relationship between responsiveness of cancer cells to Oncostatin M and/or IL‐6 and survival of stage III melanoma patients treated with tumour‐infiltrating lymphocytes

B. Dréno, A. Khammari, F. Blanchard, 2008, The Journal of pathology.